Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARG | Q86W56 | 8/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.52 |
| ▸ | MMP13 | P45452 | 1/20 | 0.48 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6730033 | 0.89 | PARG (0.52) | PARGUSP2MAPK10MMP13SLC22A8 | |
| SCHEMBL6245488 | 0.89 | MMP13 (0.60) | PARGMMP13SLC22A8TP53HDAC1 | |
| SCHEMBL27588029 | 0.88 | PARG (0.52) | PARGMMP13SLC22A8TP53HDAC1 | |
| SCHEMBL7106533 | 0.87 | MMP13 (0.59) | PARGMMP13SLC22A8HDAC1CNR2 | |
| SCHEMBL27605941 | 0.87 | PARG (0.60) | PARGMMP13SLC22A8TP53 | |
| SCHEMBL27588009 | 0.87 | PARG (0.54) | PARGMMP13SLC22A8TP53HDAC1 | |
| SCHEMBL7103213 | 0.87 | PARG (0.52) | PARGMAPK10MMP13SLC22A8TP53 | |
| SCHEMBL27588034 | 0.87 | PARG (0.52) | PARGUSP2MMP13SLC22A8TP53 | |
| SCHEMBL7634243 | 0.87 | TP53 (0.57) | PARGMMP13SLC22A8TP53HDAC1 | |
| SCHEMBL27588021 | 0.87 | PARG (0.54) | PARGMMP13SLC22A8TP53HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1368324-A1 | QUINAZOLINES AS MMP-13 INHIBITORS | Warner-Lambert Company LLC (US) | 2003-12-10 | — | — | EP | disclosed |
| US-20020193377-A1 | Quinazolines as MMP-13 inhibitors | ANDRIANJARA CHARLES (FR) | 2002-12-19 | — | — | US | disclosed |
| WO-2002064572-A1 | QUINAZOLINES AS MMP-13 INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193377-A1 | Quinazolines as MMP-13 inhibitors | MMP13, MMP9, MMP3 | PARG 3624/4885USP2 3049/4885MAPK10 2735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.